ReviewInternational ophthalmology2026
The burden of keratoconjunctivitis sicca in Nigeria: a scoping review of prevalence and risk factors.
Review in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKeratoconjunctivitis sicca, commonly known as Dry Eye Disease (DED), is a multifactorial disorder of the ocular surface characterised by tear film instability, ocular discomfort, and visual disturbance. The burden of DED has increased globally and is associated with several environmental, demographic, and ocular risk factors. Despite its growing public health importance, a comprehensive, nationally representative estimate of the prevalence and risk factors of DED in Nigeria is lacking, with existing evidence characterised by significant heterogeneity in study design, diagnostic criteria, and regional coverage. This scoping review summarises the available evidence on DED and its public health significance in Nigeria, maps knowledge gaps, and identifies areas for future research. METHODOLOGY: A comprehensive search was conducted across PubMed, Google Scholar, ScienceDirect, African Journals Online (AJOL), and grey literature for studies published within the past 18 years. Eligible studies investigated keratoconjunctivitis sicca or dry eye disease (DED) among human populations in Nigeria. Data were synthesised thematically in a narrative form. Eligible studies investigated keratoconjunctivitis sicca or dry eye disease (DED) among human populations in Nigeria. Data were synthesised thematically in a narrative form.
resultsThirteen studies (n = 4,217) conducted in Nigeria that met the inclusion criteria were included. Various study designs, including cross-sectional, longitudinal, and case-control, were represented. Across studies, the prevalence rates among adults were high, with more than a quarter of the population affected, the highest being in Oyo State. The highest clinical prevalence was observed in studies focusing on specific co-morbidities, such as 58.2% in non-diabetics in a Lagos hospital and 76% among diabetic patients in Kaduna State. Regarding demographic factors, age, gender, and educational level were identified as risk factors for DED.
conclusionKeratoconjunctivitis sicca represents a significant but often under-recognised ocular health burden in Nigeria, particularly affecting older adults, females, and individuals with systemic and environmental risk factors. DED may also contribute to visual impairment both as a primary condition and as a comorbidity. Effective prevention and management necessitate strengthening awareness, improving screening in clinical and community settings, and expanding research across underserved regions.
Indexed as
Identifiers
42397558What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.